Skip to main content
Premium Trial:

Request an Annual Quote

Not Too Shabby


According to a new American Cancer Society report, death rates from cancer fell an average 1.8 percent per year in men and 1.6 percent per year in women from 2004 to 2008, says ABC News' Katie Moisse. The report's author tells Moisse that improvements in cancer treatments, early detection, and prevention can be credited with the steady decline, which has saved a million lives during the past 18 years.

But all is not rosy. Although death rates are indeed down for lung, colorectal, breast, and prostate cancer, incidence of cancers in areas like the pancreas, liver, thyroid, and kidney are rising. In addition, although the death rates dropped in men and women from across the racial spectrum, the cancer death rate was still 33 percent higher in African-American men and 16 percent higher in African-American women than in white men and women, Moisse says. The American Cancer Society says that because the report paints a clear picture of the state of cancer care in the US, disparities based on race, ethnicity, and socioeconomic status can begin to be addressed.

Recently, a report in The Journal of Clinical Oncology further highlighted the discrepancy in cancer survival rates between white and African-American patients.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.